Tocilizumab Injection IP

Key Benefits
- Helps reduce inflammation associated with autoimmune disorders
- Supports management of rheumatoid arthritis
- Helps improve joint pain, swelling, and stiffness
- May support treatment of selected forms of juvenile idiopathic arthritis
- Helps reduce excessive IL-6-mediated immune activity
- May improve physical function and disease-related symptoms in appropriate patients
How It Works
Tocilizumab binds to interleukin-6 receptors and blocks IL-6 signaling, an important pathway involved in inflammation and immune-system activity. By reducing this signaling, it helps decrease inflammatory responses and associated symptoms.
Common Side Effects
- Upper respiratory tract infections
- Headache
- Increased blood pressure
- Injection-site reactions
- Nausea
- Abdominal discomfort
- Elevated liver enzymes
- Changes in blood cell counts
Important Information
Tocilizumab Injection IP should be administered under the supervision of a qualified healthcare professional. Because it can suppress immune activity, it may increase the risk of serious infections, including tuberculosis and other infections. Screening for tuberculosis and hepatitis may be recommended before treatment. Regular monitoring of blood counts, liver function, and lipid levels may be required. Tocilizumab can also increase the risk of gastrointestinal complications in susceptible patients. Seek medical attention for persistent fever, severe abdominal pain, breathing difficulty, or signs of a serious infection or allergic reaction.